978 Eli Lilly and Company $LLY Shares Acquired by Veracity Capital LLC

Key Points

• Veracity Capital increased its Eli Lilly stake by 52.2% in the third quarter, bringing its holdings to 2,850 shares valued at approximately $3.3 million. Institutional investors collectively own 82.53% of LLY.
• Analysts remain broadly bullish, with a consensus “Moderate Buy” rating and an average price target of $1,313.43. Recent quarterly results also exceeded expectations, with EPS of $8.38 and revenue of $22.97 billion.
• Lilly’s obesity-drug pipeline, particularly retatrutide, remains a major growth catalyst, but its premium valuation and competition in weight-loss treatments present risks. Shares recently traded at $1,151.21, below the consensus target.

Veracity Capital LLC raised its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 52.2% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,850 shares of the company's stock after buying an additional 978 shares during the quarter. Eli Lilly and Company comprises 0.9% of Veracity Capital LLC's portfolio, making the stock its 16th largest holding. Veracity Capital LLC's holdings in Eli Lilly and Company were worth $3,298,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of LLY. Integrity Financial Corp WA lifted its stake in Eli Lilly and Company by 1.3% in the 2nd quarter. Integrity Financial Corp WA now owns 639 shares of the company's stock worth $767,000 after purchasing an additional 8 shares in the last quarter. Willner & Heller LLC boosted its stake in Eli Lilly and Company by 1.0% during the second quarter. Willner & Heller LLC now owns 917 shares of the company's stock worth $1,100,000 after buying an additional 9 shares during the last quarter. Aspiring Ventures LLC grew its holdings in Eli Lilly and Company by 3.7% in the 2nd quarter. Aspiring Ventures LLC now owns 255 shares of the company's stock valued at $306,000 after buying an additional 9 shares in the last quarter. Wealthspan Partners LLC increased its stake in shares of Eli Lilly and Company by 0.4% in the 2nd quarter. Wealthspan Partners LLC now owns 2,120 shares of the company's stock worth $2,543,000 after acquiring an additional 9 shares during the last quarter. Finally, Navigoe LLC raised its holdings in shares of Eli Lilly and Company by 8.7% during the 2nd quarter. Navigoe LLC now owns 113 shares of the company's stock worth $135,000 after acquiring an additional 9 shares during the period. 82.53% of the stock is currently owned by institutional investors.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Higher analyst price target: Cantor Fitzgerald raised its target for Eli Lilly from $1,410 to $1,440 and maintained an “overweight” rating, implying substantial upside based on expectations for continued earnings and pipeline growth.
• Positive Sentiment: Obesity pipeline remains a major catalyst: Analysts point to retatrutide, Lilly’s next-generation triple-hormone weight-loss candidate, as a potential successor to Mounjaro and Zepbound. Its reported clinical weight-loss results and potential applications in related conditions could expand Lilly’s long-term addressable market. Eli Lilly's Obesity Business Could Become a Much Bigger Healthcare Platform
• Positive Sentiment: Pipeline diversification continues: Lilly is testing eloralintide in an obesity-related study involving hormonal contraception and has initiated an early-stage Alzheimer’s trial. These studies are preliminary, but they reinforce the company’s efforts to build growth beyond its current GLP-1 franchise. Eli Lilly Tests Obesity Drug Eloralintide With Birth Control
• Positive Sentiment: Oncology and technical support: Jaypirca, Inluriyo and Retevmo could help offset slowing Verzenio sales, while a move above the 50-day moving average is viewed by some technical analysts as a short-term bullish signal.
• Neutral Sentiment: Investor sentiment remains constructive: Commentary highlights Lilly’s “growth flywheel” from GLP-1 demand, manufacturing expansion, new indications and earnings growth. However, these are largely forward-looking investment opinions rather than new financial results.
• Negative Sentiment: Valuation and competition remain concerns: Lilly trades at a premium multiple, leaving the stock vulnerable to profit-taking if obesity-drug growth slows, pricing pressure increases or Novo Nordisk and other competitors gain share. LLY Stock Down 2% in 3 Months
• Negative Sentiment: New obesity guidelines could create uncertainty: The World Health Organization’s childhood-obesity recommendations may increase scrutiny of how weight-loss medicines are used in younger populations, potentially affecting future market expectations for Lilly and Novo Nordisk.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the stock. Bank of America lifted their price target on shares of Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the company a "buy" rating in a research report on Friday, July 10th. Morgan Stanley upped their price target on Eli Lilly and Company from $1,419.00 to $1,430.00 and gave the company an "overweight" rating in a research note on Wednesday. The Goldman Sachs Group raised their price objective on Eli Lilly and Company from $1,367.00 to $1,371.00 and gave the stock a "buy" rating in a research report on Thursday, September 17th. Wells Fargo & Company upped their target price on shares of Eli Lilly and Company from $1,280.00 to $1,330.00 and gave the company an "overweight" rating in a research report on Thursday, August 6th. Finally, BMO Capital Markets reaffirmed an "outperform" rating on shares of Eli Lilly and Company in a research note on Thursday, October 1st. One analyst has rated the stock with a Strong Buy rating, twenty-five have assigned a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $1,313.43.

Eli Lilly and Company Stock Performance

Shares of LLY traded down $37.51 during trading hours on Thursday, reaching $1,151.21. 1,719,061 shares of the company traded hands, compared to its average volume of 2,967,456. The stock has a market capitalization of $1.08 trillion, a P/E ratio of 38.63, a P/E/G ratio of 1.42 and a beta of 0.46. The company has a quick ratio of 1.00, a current ratio of 1.35 and a debt-to-equity ratio of 1.41. The business has a fifty day moving average price of $1,173.51 and a 200-day moving average price of $1,094.59. Eli Lilly and Company has a 12-month low of $783.85 and a 12-month high of $1,292.65.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The company reported $8.38 EPS for the quarter, topping the consensus estimate of $6.40 by $1.98. The business had revenue of $22.97 billion for the quarter, compared to analyst estimates of $20.82 billion. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%.The business's quarterly revenue was up 47.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $6.31 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Equities analysts anticipate that Eli Lilly and Company will post 36.66 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CAO Donald A. Zakrowski sold 2,000 shares of the firm's stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the sale, the chief accounting officer owned 1,526 shares of the company's stock, valued at $1,808,325.26. This trade represents a 56.72% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the firm's stock in a transaction on Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total value of $5,950,000.00. Following the completion of the sale, the executive vice president owned 11,875 shares in the company, valued at approximately $14,131,250. This represents a 29.63% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 13,500 shares of company stock worth $15,958,170 over the last ninety days. Corporate insiders own 0.14% of the company's stock.

About Eli Lilly and Company

Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana. Founded in 1876 by Colonel Eli Lilly, the company researches, develops, manufactures and markets medicines for a range of conditions, including diabetes, obesity, cancer, immunological disorders, neurological diseases and pain.

Its products include Mounjaro and Zepbound, which contain tirzepatide and are used for type 2 diabetes and chronic weight management, respectively. Other key medicines include Trulicity for diabetes, Verzenio for certain breast cancers, Taltz for inflammatory and autoimmune conditions, Humalog insulin, and Kisunla for early symptomatic Alzheimer's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.